196.79
-10.01 (-4.84%)
| Penutupan Terdahulu | 206.80 |
| Jumlah Dagangan | 6,912,807 |
| Harga / Jualan (P/S) | 32.54 |
| Harga / Buku (P/B) | 12.22 |
| Julat 52 Minggu |
| Margin Keuntungan | -105.67% |
| Margin Operasi (TTM) | -972.22% |
| EPS Cair (TTM) | -8.73 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -35.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.40% |
| Nisbah Semasa (MRQ) | 4.22 |
| Aliran Tunai Operasi (OCF TTM) | -3.05 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.20 B |
| Pulangan Atas Aset (ROA TTM) | -15.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.34% |
Sentimen Berita
-
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
3 hari lalu, 7:13AM
-
Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
12 Nov, 4:14PM
-
Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development
12 Nov, 7:26AM
-
Moderna Sinks 7% as Analyst Day Cancer Push Brings “$4 Billion in Cash Costs in 2027”
12 Nov, 1:38PM
-
While Moderna sank 17%, this generic drugmaker quietly jumped 64%
2 hari lalu, 3:27AM
-
Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.
2 hari lalu, 12:20AM
AISkor Stockmoo
| Nilai 30% | -3.0 |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | 1.6 |
| Aliran menaik sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.4 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 0.3 |
| Institusi bersih +0.11% daripada saham dalam pemfailan 13F terkini: 677 pemegang menambah, 357 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -15.2% dari 31 Aug hingga 30 Oct 2026, 1.8 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham kebanyakannya menurun. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di atas garis aliran jangka sederhana. info | |
| Harga tinggi berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | -0.28 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Moderna, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| MRNA | - | - | - | 12.22 | -0.3 |
| KOD | 6 B | - | - | 500.31 | 0.0 |
| PTCT | 5 B | - | - | - | 0.0 |
| ABCL | 3 B | - | - | 3.39 | -0.5 |
| DNLI | 3 B | - | - | 3.18 | -2.1 |
| CELC | 3 B | - | - | 83.17 | -1.5 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.28% |
| % Dimiliki oleh Institusi | 73.67% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 90.07%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 677 | 36,557,615 |
| Berkurang | 357 | 40,275,883 |
| Baharu | 353 | 5,764,990 |
| Dijual habis | 76 | 1,618,068 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 33,191,285 | 1.8 |
| 15 Oct 2026 | 32,603,398 | 1.8 |
| 30 Sep 2026 | 30,863,202 | 1.8 |
| 15 Sep 2026 | 32,872,787 | 2.5 |
| 31 Aug 2026 | 39,151,532 | 1.0 |
| 14 Aug 2026 | 52,809,184 | 9.1 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Nov 2026 | Yahoo Finance |
While Moderna sank 17%, this generic drugmaker quietly jumped 64%
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below. |
| 19 Nov 2026 | Yahoo Finance |
Moderna (MRNA) Dropped, So What Is Behind The Latest Attention?
Moderna (MRNA) just reworked its debt deal, cutting interest margins on existing and delayed draw term loans by 0.75 percentage points, and pushing key maturities and borrowing availability further into the next decade. Moderna sits at US$196.79 after a sharp 1-day share price return of down 4.84%… |
| 19 Nov 2026 | Yahoo Finance |
Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.
Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's why. |
| 18 Nov 2026 | Yahoo Finance |
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
Moderna (NASDAQ:MRNA) is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data. At a Jefferies investor session, Head of Investor Relations L… |
| 17 Nov 2026 | Yahoo Finance |
JPMorgan Still Sees Moderna Overvalued Despite Raising Its Target
The firm sees a gap between Moderna's $87.1 billion market value and what its pipeline can justify… |
| 17 Nov 2026 | Yahoo Finance |
Moderna's INT Outlook Strengthens After Phase 3 Melanoma Data, Morgan Stanley Says
Moderna's (MRNA) phase 3 adjuvant melanoma data establishes clinical proof of concept for individual… |
| 17 Nov 2026 | Yahoo Finance |
At $215, Moderna Stock Already Prices In A Comeback
Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash. |
| 16 Nov 2026 | Yahoo Finance |
Is Moderna's Cancer Vaccine a Game Changer for the Stock?
The healthcare stock has hit multi-year highs this year amid positive results from its personalized cancer vaccine. |
| 16 Nov 2026 | Yahoo Finance |
Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive
One melanoma headline turned a $63 stock into a market darling, and Moderna's CEO just told Jim Cramer when patients could get the shot. Does the price already bake in the cancer breakthrough, or is the next catalyst still ahead? |
| 16 Nov 2026 | Yahoo Finance |
Proshares Trust (TQQQ) Buys $72.9 Million More Moderna on Nov. 12
The 3x leveraged Nasdaq-100 fund added a $72.9 million Moderna stake while trimming 100 positions and net selling $101.1 million. |
| 16 Nov 2026 | Yahoo Finance |
What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 12
The fund added $319.5 million in gross purchases, lifting all 503 positions and making no sales. |
| 16 Nov 2026 | Yahoo Finance |
Moderna (MRNA) Sees $109.7 Million in Net ETF Buying on Nov. 12
ETFs bought $109.7 million of Moderna stock on Thursday, Nov. 12… |
| 14 Nov 2026 | Yahoo Finance |
Moderna Sinks 12% in a Week. Bancel Wants an FDA Filing “Before the End of the Year”
Key TakeawaysModerna fell 12% in the week to Nov. 13 after guiding to about $4 billion or more of cash costs a year through 2030, mostly for cancer drugs. |
| 14 Nov 2026 | Yahoo Finance |
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors. |
| 13 Nov 2026 | Yahoo Finance |
The Single Most Important Metric For Moderna Stock
For questions about this article or underlying research, email [email protected]. |
| 13 Nov 2026 | Yahoo Finance |
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment. |
| 13 Nov 2026 | Yahoo Finance |
What Invesco S&P 500 Equal Weight ETF (RSP) Sold: Moderna Leads on Nov. 11
The $105.70 billion fund sold $93.1 million of stock on Wednesday, trimming 502 positions and adding to none. |
| 12 Nov 2026 | Yahoo Finance |
GSK (LSE:GSK) Settles Key Vaccine Patent Case And Wins Broad Europe Injunction
GSK (LSE:GSK) reached a cross-licensing agreement with Moderna resolving their COVID-19 vaccine patent dispute in Europe. The pharma group secured a significant injunction against Pfizer-BioNTech covering liposome delivery technology used in RNA vaccines across multiple European markets. Ongoing… |
| 12 Nov 2026 | Yahoo Finance |
Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
Moderna (NASDAQ:MRNA) is preparing to seek U.S. approval of its individualized cancer treatment intismeran by year-end, with executives aiming for a 2027 launch alongside partner Merck if regulators approve the therapy. At an investor event in Marlborough, Massachusetts, company leaders highlighted… |
| 12 Nov 2026 | Yahoo Finance |
Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine. |
| 12 Nov 2026 | Yahoo Finance |
Moderna Sinks 7% as Analyst Day Cancer Push Brings “$4 Billion in Cash Costs in 2027”
Key TakeawaysModerna shares fell 7% today after the company guided to cash costs of about $4 billion in 2027 and $4 billion to $4. 5 billion a year through 2030, mostly for oncology. |
| 12 Nov 2026 | Yahoo Finance |
Why Is Moderna (MRNA) Joining A Global Benchmark And Publishing New Vaccine Data?
Moderna (NasdaqGS:MRNA) is scheduled to join the MSCI World Index in November 2026, which would add the stock to a major global benchmark. The biotech group reported publication of real world data on its mNEXSPIKE COVID-19 vaccine in older adults in a peer reviewed journal. The new study compared… |
| 12 Nov 2026 | Yahoo Finance |
Why Moderna Stock Dropped on Thursday
Moderna promised 20% sales growth in 2026 -- but Wall Street wants 24%. |
| 12 Nov 2026 | Yahoo Finance |
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential. |
| 12 Nov 2026 | Yahoo Finance |
Merck’s Keytruda Combo Cut Melanoma Recurrence or Death Risk 42%. What the February 2 Report Has to Prove
Key TakeawaysModerna said on Nov. 6 that it and Merck plan to file intismeran, which cut melanoma recurrence or death risk 42% with Keytruda, this year. |
| 12 Nov 2026 | Yahoo Finance |
Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development
Moderna, Inc. (NASDAQ:MRNA) increased its 2026 revenue growth forecast to between 15% and 25%, compared with its previous outlook of up to 10%, as the biotechnology company outlined financial expectations and clinical development updates during its 2026 Analyst Day in Cambridge, Massachusetts. |
| 12 Nov 2026 | Yahoo Finance |
Moderna Outlines Next Phase of Growth at Analyst Day
Moderna also provided updates on commercial growth, oncology pipeline progress, manufacturing readiness and mid-term financial objectives."We founded Moderna on the belief that mRNA could transform medicine, and over the past decade we have built a powerful platform to realize that vision," said… |
| 12 Nov 2026 | Yahoo Finance |
What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 10
The fund added $739.1 million in net buys against $757.9 million gross traded, lifting 501 positions while trimming just one. |
| 11 Nov 2026 | Yahoo Finance |
Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
Real-world analysis of more than 294,000 U. Veterans aged 65 and older found mNEXSPIKE was associated with a 35… |
| 11 Nov 2026 | Yahoo Finance |
Moderna Stock Jumped 10% in 5 Sessions: Take Profits, or Buy More?
Key TakeawaysModerna (MRNA) stock gained approximately 9. 8% over five trading sessions, closing at $250… |
| 11 Nov 2026 | Yahoo Finance |
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
Analysts have placed intismeran central to Moderna’s long-term growth beyond infectious diseases. |
| 10 Nov 2026 | Yahoo Finance |
Why is Moderna (MRNA) stock soaring today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after the company reported third-quarter 2026 financial results, with revenue rising 29% to $1.3 billion, and raised its full-year revenue growth forecast. |
| 10 Nov 2026 | Yahoo Finance |
Moderna to Present at Upcoming Conference in November 2026
CAMBRIDGE, MA / ACCESS Newswire / November 10, 2026 / (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Jefferies Global Health Care Conference, on Wednesday, November 18th 11:00am GMTA live webcast of each of these presentations will be available under… |
| 10 Nov 2026 | Yahoo Finance |
“More Cancers Than Melanoma”: Moderna Is Up 750% in 2026. Take Profits, or Buy More?
Key TakeawaysModerna stock is up 750% in 2026, mostly on its melanoma vaccine with Merck, which succeeded in Phase 3. Third-quarter revenue rose 29% on COVID deals abroad, while Pfizer’s rival shot sold less. |
| 10 Nov 2026 | Yahoo Finance |
What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 6
The fund added $291.5 million in gross purchases on Friday, increasing all 503 positions and selling nothing. |
| 09 Nov 2026 | Yahoo Finance |
Why Did U, MRNA, ABNB Stocks Surge To 52-Week Highs Today?
Investors showed interest in AI gaming tools, advances in cancer vaccines and future business growth. |
| 09 Nov 2026 | Yahoo Finance |
Is Moderna (MRNA) Priced For Too Much Sales Growth?
Moderna has turned into one of the market’s sharpest movers, and after such a powerful run, the key issue for you is whether the current share price still lines up with what its sales can support. A stock can move very quickly when sentiment swings on new data or approvals, so the question is how… |
| 09 Nov 2026 | Yahoo Finance |
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the past five years. |
| 06 Nov 2026 | CNBC |
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |